HFA 23: DAPA-RESIST: Dapagliflozin Vs Metolazone in Patients With Heart Failure and Diuretic Resistance

Published: 22 May 2023

  • Views:

    Views Icon 555
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

ESC-HFA 23 – Dr Ross Campbell (University of Glasgow, UK) joins us onsite to discuss the findings of the DAPA-RESIST Trial, which aimed to assess the affect of dapagliflozin as compared to metolazone in heart failure patients with diuretic resistance (NCT04860011).

In this phase 3 trial, investigators studied whether SGLT2i led to greater diuresis in this patient group, as to the standard practice use of metolazone in addition to furosemide. 61 patients were enrolled into the study. Findings suggest that both dapagliflozin and metolazone were well-tolerated and effective at treating diuretic resistance in this cohort of patients. 

Interview Questions:

  1. What is the rationale for this pragmatic trial?
  2. What was study design, patient population and outcome measures?
  3. What is the key data presented at HFA 23?
  4. What are the take-home messages of practicing clinicians?
  5. How do these findings complement the results of EMPEROR-Preserved and DELIVER?
  6. What are the next steps?

Recorded on-site at HFA 23, Prague.

Explore more content from the ESC Heart Failure 2023 Late-breaking Science Collection.

Editors: Jordan Rance, Mirjam Boros

Video Specialist: Tom Green, Dan Brent


You must be to comment. If you are not registered, you can register here.